Biological activities of salvianolic acid B from Salvia miltiorrhiza on type 2 diabetes induced by high-fat diet and streptozotocin
Biological activities of salvianolic acid B from Salvia miltiorrhiza on type 2 diabetes induced by high-fat diet and streptozotocin
复制标题
丹参丹酚酸B对高脂饮食和链脲佐菌素诱导的2型糖尿病的生物活性
DOI：
10.3109/13880209.2014.959611
复制
发表时间：
2015-01-01
影响因子：
3.8
通讯作者：
Lu, Jinjian
中科院分区：
文献类型：
--
作者：
Huang, Mingqing;Wang, Peijian;Lu, Jinjian
摘要背景：丹参Bge。（Labibiridine）已被广泛用于治疗糖尿病几个世纪。丹参酸B（SalB）是丹参中的主要活性成分，但其抗糖尿病活性及其可能机制尚不清楚。目的：目的：探讨SalB对2型糖尿病大鼠糖代谢、脂代谢、胰岛素抵抗、氧化应激及糖原合成的影响。材料与方法：将高脂饮食（HFD）和链脲佐菌素（STZ）诱导的糖尿病大鼠随机分为模型组、SalB组（50、100、200 mg/kg）和罗格列酮组。结果如下：与模型组相比，SalB（100和200 mg/kg）组血糖和胰岛素水平分别降低23.8和21.7%（p < 0.05和p < 0.01）和31.3和26.6%（p < 0.05），胰岛素敏感性指数分别升高10.9和9.3%（p < 0.05）。他们还显着降低总胆固醇（分别为24.9%和27.9%; p < 0.01），低密度脂蛋白胆固醇（56.2%和64.6%; p < 0.01），非酯化脂肪酸（分别为32.1%和37.9%; p < 0.01），肝糖原（分别为41.3%和60.5%; p < 0.01），肌糖原（分别增加33.2和38.6%; p < 0.05），并增加高密度脂蛋白胆固醇（分别增加50.0和61.4%; p < 0.05和p < 0.01），这些都是最初被HFD和链脲佐菌素改变的。此外，SalB（200 mg/kg）显著降低甘油三酯和丙二醛（分别为31.5%和29.0%; p < 0.05和p < 0.01），并增加超氧化物歧化酶（分别为56.6%; p < 0.01），而这些变化最初是由HFD和链脲佐菌素引起的。讨论与结论：结果表明，SalB能抑制糖尿病大鼠的症状，其作用可能部分与其胰岛素敏感性、糖原合成和抗氧化活性有关。
Abstract Context: Salvia miltiorrhiza Bge. (Labiatae) has been widely used for treating diabetes for centuries. Salvianolic acid B (SalB) is the main bioactive component in Salvia miltiorrhiza; however, its antidiabetic activity and possible mechanism are not yet clear. Objective: To investigate the effects of SalB on glycometabolism, lipid metabolism, insulin resistance, oxidative stress, and glycogen synthesis in type 2 diabetic rat model. Materials and methods: High-fat diet (HFD) and streptozotocin-induced diabetic rats were randomly divided into model group, SalB subgroups (50, 100, and 200 mg/kg), and rosiglitazone group. Results: Compared with the model group, SalB (100 and 200 mg/kg) significantly decreased blood glucose (by 23.8 and 21.7%; p < 0.05 and p < 0.01) and insulin (by 31.3 and 26.6%; p < 0.05), and increased insulin sensitivity index (by 10.9 and 9.3%; p < 0.05). They also significantly decreased total cholesterol (by 24.9 and 27.9%; p < 0.01), low-density lipoprotein cholesterol (by 56.2 and 64.6%; p < 0.01), non-esterified fatty acids (by 32.1 and 37.9%; p < 0.01), hepatic glycogen (by 41.3 and 60.5%; p < 0.01), and muscle glycogen (by 33.2 and 38.6%; p < 0.05), and increased high-density lipoprotein cholesterol (by 50.0 and 61.4%; p < 0.05 and p < 0.01), which were originally altered by HFD and streptozotocin. In addition, SalB (200 mg/kg) markedly decreased triglyceride and malondialdehyde (by 31.5 and 29.0%; p < 0.05 and p < 0.01), and increased superoxide dismutase (by 56.6%; p < 0.01), which were originally altered by HFD and streptozotocin. Discussion and conclusion: The results indicate that SalB can inhibit symptoms of diabetes mellitus in rats and these effects may partially be correlated with its insulin sensitivity, glycogen synthesis and antioxidant activities.